donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
SUPN Supernus Pharmaceuticals
32.790
+1.530+4.89%
Post Mkt Price
32.79000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
24.47% 335.2041 35.21% 364.9815 33.78% 380.085 33.78% 380.085
Receivable Turnover(T)
-1.42% 4.2668 -2.22% 4.4182 -12.27% 4.0011 -12.27% 4.0011
Inventory Turnover(T)
-39.84% 1.0257 -33.76% 1.1227 -20.13% 1.1179 -20.13% 1.1179
Fixed Assets Turnover(T)
160.41% 37.7491 52.58% 21.8018 54.92% 21.1678 54.92% 21.1678
Total Asset Rate(T)
3.47% 0.3856 -7.36% 0.3822 -7.04% 0.3631 -7.04% 0.3631
ROIC
-54.3% 4.384% -45.81% 5.825% -57.34% 5.230% -57.34% 5.230%
ROE
-48.81% 7.066% -42.96% 9.267% -63.86% 6.846% -63.86% 6.846%
ROA
-46.2% 3.518% -43.43% 4.661% -64.89% 3.346% -64.89% 3.346%
FCF to Sales
-8.16% 19.000% -46.57% 15.680% -16.81% 21.574% -16.81% 21.574%
FCF to Net Income
76.63% 208.254% -12.49% 128.561% 120.25% 234.131% 120.25% 234.131%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -33.48% 20.623% -- --
ROA 5 Year Average
-- -- -- -- -37.74% 10.978% -- --
Average 5 Years ROIC
-- -- -- -- -42.42% 14.326% -- --
Profitability Ratios TTM
Gross Margin
2.71% 88.340% -1.81% 87.023% -3.19% 87.053% -3.19% 87.053%
Operating Margin
-64.8% 8.669% -60.94% 11.291% -59.36% 13.712% -59.36% 13.712%
Net Margin
-48% 9.124% -38.94% 12.197% -62.23% 9.215% -62.23% 9.215%
EBITDA Margin
-33.85% 0.2142% -32.78% 0.2388% -44.92% 0.2228% -44.92% 0.2228%
R & D Expense Ratio
-16.42% 12.370% -21.94% 12.810% 6.85% 15.600% 6.85% 15.600%
Sales Expense Ratio
35.88% 39.200% 42.34% 36.880% 33.06% 34.450% 33.06% 34.450%
Administration Expense Rate
38.06% 18.680% 35.62% 18.620% 43.01% 18.120% 43.01% 18.120%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-91.48% 4.407% -2.94% 53.144% -6.48% 51.547% -6.48% 51.547%
Total Assets to Common Equity
0.6% 201.439% -0.95% 197.903% 2.53% 207.042% 2.53% 207.042%
Debt to Asset Ratio
0.74% 52.889% -2.58% 53.886% -5.9% 52.341% -5.9% 52.341%
Current Ratio
-62.32% 0.8499 -17.9% 1.9979 -25.84% 1.9075 -25.84% 1.9075
Quick Ratio
-63.45% 0.7054 -25.31% 1.6072 -32.6% 1.5493 -32.6% 1.5493
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -37.84% 12.344% -- --
Revenue CAGR(5Y)
-- -- -- -- -24.9% 21.945% -- --
Net Income CAGR(3Y)
-- -- -- -- -171.21% -21.630% -- --
Net Income CAGR(5Y)
-- -- -- -- -118.32% -10.148% -- --
FCF 1 Year Growth
-- -- -- -- -88.61% -7.312% -- --
FCF CAGR(3Y)
-- -- -- -- -112.9% -0.802% -- --
FCF CAGR(5Y)
-- -- -- -- -60.32% 13.914% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
CEO: Khattar, Jack A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...